14 April 2025
Nuformix plc
("Nuformix" or the "Company")
Exercise of Warrants
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has received a notice of exercise of broker warrants to subscribe for a total of 26,400,000 new ordinary shares of 0.05 pence each in the capital of the Company ("Ordinary Shares") (the "New Ordinary Shares"). The New Ordinary Shares are being issued at a price of 0.05 pence per share, for a total consideration to the Company of £13,200.
The New Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for the New Ordinary Shares to be admitted to the Official List of the FCA and to trading on the Main Market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective and dealings in the New Ordinary Shares will commence at 8.00 a.m. on 18 April 2025.
Total Voting Rights
Upon Admission, the Company's issued share capital will consist of 1,695,709,368 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 1,695,709,368. With effect from Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
| Nuformix plc |
|
| Dr Dan Gooding, Executive Director
| Via IFC Advisory
|
| CMC Markets | |
| Douglas Crippen | +44 (0) 20 3003 8632 |
| | |
| IFC Advisory Limited | |
| Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
